BioNexus gets rights to build and sublicense healthcare software in Malaysia, but would issue shares equal to about 16% of its share count after issuance and pay a 10% royalty on covered sales. Closing still depends on checks and approvals, so these mixed terms do not clearly change its outlook.
The platform could let BioNexus build and sublicense healthcare software in Malaysia. But the deal would give RYET shares equal to about 16% of BioNexus after issuance, plus a 10% royalty on covered sales. Closing still depends on checks and approvals, so the opportunity and its costs leave the outlook without a clear change.
RYET grants BioNexus exclusive Malaysian healthcare rights and keeps a royalty on covered receipts, but receives BioNexus shares rather than cash for the license. The exchange of shares and platform rights leaves RYET's outlook without a clear change.
Follow BioNexus Gene Lab Corp (BGLC) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for BGLC